Antroquinonol (Hocena), an anti-cancer and anti-hyperlipidemia drug developed by a Taiwanese firm as a potential medicine to treat COVID-19, was approved by Peru's authorities to begin phase II trials, according to its developer.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Think tank raises Taiwan 2024 GDP growth to 3.38% amid export optimism
04/19/2024 05:33 PM - Politics
Premier-designate Cho picks labor, health, environment ministers (update)
04/19/2024 04:26 PM - Business
U.S. dollar closes sharply higher on Taipei forex market
04/19/2024 04:11 PM - Politics
Over NT$20 billion to be allocated to Hualien earthquake relief
04/19/2024 03:48 PM - Politics
Computer-aided Han Kuang war games to refer to recent conflicts
04/19/2024 03:23 PM